Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Enzalutamide alone or combined with other pharmacologic agents for metastatic castration-resistant prostate cancer: A systematic review and meta-analysis.

Created on 30 Oct 2026

Authors

Yeison Cruz Castillo, Alejandro Chen Liang, Victor M Samperio, Alexa Bentley, Elizabeth Olive Roberts Trinidad, Ion Codreanu, Constantin A Dasanu

Published in

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. Pages 10781552261497638. Oct 30, 2026. Epub Oct 30, 2026.

Abstract

BackgroundMetastatic castration-resistant prostate cancer (mCRPC) remains driven by persistent androgen receptor signaling. Although enzalutamide (ENZ) is widely used, the incremental benefit of adding other agents remains uncertain. We evaluated the efficacy and safety of specific pharmacologic agents added to ENZ in randomized trials.MethodsWe systematically searched PubMed/MEDLINE, Web of Science, CINAHL, and Scopus through September 2026 following PRISMA guidelines (PROSPERO: CRD420251231232). RCTs comparing ENZ plus another pharmacologic agent with ENZ monotherapy in mCRPC were included. Analyzed outcomes included overall survival (OS), progression-free survival (PFS), radiographic PFS (rPFS), PSA progression, and adverse events. Random-effects meta-analyses used restricted maximum likelihood estimation with Hartung-Knapp adjustment. Certainty of evidence was assessed using GRADE.ResultsNine trials involving 3779 patients were included. Adding specific agents to ENZ improved rPFS (HR = 0.76; 95% CI, 0.62-0.94; p = 0.02) but did not significantly improve OS, PFS, or PSA progression. Combination therapy increased the risk of any adverse event (RR = 1.03; 95% CI, 1.01-1.06) and grade ≥3 adverse events (RR = 1.37; 95% CI, 1.09-1.71). Estimates for individual adverse events were inconsistent and imprecise.ConclusionAdding specific agents to ENZ improved pooled rPFS but increased toxicity, without clear evidence of an OS benefit in unselected mCRPC populations (certainty of evidence ranging from very low to moderate across outcomes). These findings should be interpreted cautiously and do not exclude potential benefits from particular combinations in biomarker-selected populations.

PMID:
42961340
Bibliographic data and abstract were imported from PubMed on 30 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 18
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement